Zynex Q1 revenue up 10% to $46.5M; net income near zero; orders up 23% YoY

ZYNEX INC

2024-Q1 EPS reported $0.00 revenue$46,531,000

Q1 revenue $46.5M (+10% YoY); missed $47.5M guidance due to cyber incident delaying insurer payments; full-year $227M guide reaffirmed.
Net income $10,000 ($0.00 diluted EPS); adjusted EBITDA $1.7M; orders hit eighth consecutive quarterly record, up 23% YoY.
Repurchased $13.4M of stock in Q1; $78.5M over past 24 months.
FDA clearance for next-gen M-Wave NMES device; launched Zynex Pro Hybrid LSO and DynaComp Cold Compression therapy products.
Q2 guidance: revenue at least $52M, diluted EPS at least $0.08; FY 2024: revenue at least $227M, diluted EPS at least $0.50.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ZYNEX INC reported the first quarter of 2024 results: revenue $46.5 million, net income $10,000, EPS $0.00. Guidance reaffirmed.

Period: the first quarter of 2024
Revenue: $46.5 million
Net income: $10,000
EPS: $0.00
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Zynex Reports First Quarter 2024 Financial Results Q1 2024 Revenue Increased 10% to $46.5 Million

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001558370-24-006269

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.